[Retracted] Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C

Table 2

Distribution of patients with ALT <40 U/L at different time periods.

Indicators (months)	Control group (n = 26)	Tenofovir group (n = 26)	Entecavir group (n = 26)
3	7 (26.92%)	15 (57.68%)#&	12 (46.15%)#
6	10 (38.46%)^∗	20 (76.92%)^∗#&	17 (65.38%)^∗#
12	12 (46.15%)^∗@	23 (88.46%)^∗@#&	20 (76.92%)^∗@#